Intra-Cellular Therapies, Inc.(ITCI) Stock Research - Grey Stern Research

Intra-Cellular Therapies, Inc. (ITCI) Stock Analysis

$75.26 (-0.16%)

ITCI Financial Performance


Use the table below to view Intra-Cellular Therapies, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $75.22 -
52 Week Low $45.50 -
52 Week High $84.89 -
Market Cap $7.9 Billion 2/14
Gross Margin 93% 3/14
Profit Margin -10% 11/14
EBITDA margin -17% 12/14
Q2 - 2024 Revenue $161.4 Million 6/14
Q2 - 2024 Earnings -$16.2 Million 13/14
Q2 - 2024 Free Cash Flow $489,000 Million 9/14
Trailing 4 Quarters Revenue $563.6 Million 7/14
Trailing 4 Quarters Earnings -$84.3 Million 12/14
Quarterly Earnings Growth 62% 4/14
Annual Earnings Growth 52% 9/14
Quarterly Revenue Growth 47% 2/14
Annual Revenue Growth 43% 2/14
Cash On Hand $695.1 Million 1/14
Short Term Debt $4.2 Million 9/14
Long Term Debt $14.1 Million 13/14

Intra-Cellular Therapies, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Intra-Cellular Therapies, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 10/14
PS 14.10 2/14
PB 6.94 2/14
PC 11.44 7/14
Liabilities to Equity 0.15 10/14
ROA -0.06 11/14
ROE -0.07 12/14
Current Ratio 7.51 1/14
Quick Ratio 5.83 1/14
Long Term Debt to Equity 0.01 10/14
Debt to Equity 0.02 10/14
Burn Rate 38.99 1/14
Cash to Cap 0.09 8/14
CCR -0.03 10/14
EV to EBITDA -263.52 14/14
EV to Revenue 12.90 2/14

Company Details

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

CEO: Dr. Sharon Mates

Website: https://www.intracellulartherapies.com

Address: 430 E 29th St New York City, NEW YORK

Exchange: NASDAQ Global Select

Industry: Drug Manufacturers—Specialty & Generic

Intra-Cellular Therapies, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Intra-Cellular Therapies, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dynavax Technologies Corporation DVAX $1.5 Billion
Pacira BioSciences, Inc. PCRX $604.7 Million
Neurocrine Biosciences, Inc. NBIX $12.3 Billion
Ironwood Pharmaceuticals, Inc. IRWD $730.0 Million
Collegium Pharmaceutical, Inc. COLL $1.2 Billion
Eagle Pharmaceuticals, Inc. EGRX $56.0 Million
Alkermes plc ALKS $4.6 Billion
ANI Pharmaceuticals, Inc. ANIP $1.2 Billion
Amphastar Pharmaceuticals, Inc. AMPH $2.3 Billion
Deciphera Pharmaceuticals, Inc. DCPH $2.2 Billion
Amneal Pharmaceuticals, Inc. AMRX $2.7 Billion
Aquestive Therapeutics, Inc. AQST $440.7 Million
Cyclo Therapeutics, Inc. CYTH $18.6 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ITCI Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 161.4 Million -$16.2 Million
Q1 2024 $ 144.9 Million -$15.2 Million
Q4 2023 $ 131.5 Million -$28.6 Million
Q3 2023 $ 125.8 Million -$24.3 Million
Q2 2023 $ 110.1 Million -$42.8 Million
Q1 2023 $ 94.7 Million -$44.1 Million
Q4 2022 $ 87.4 Million -$37.3 Million
Q3 2022 $ 71.9 Million -$53.5 Million

View All

ITCI Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $695.1 Million $1.3 Billion $18.3 Million $1.1 Billion
Q1 2024 $141.6 Million $747.0 Million $16.4 Million $599.5 Million
Q4 2023 $147.8 Million $728.3 Million $16.9 Million $591.4 Million
Q3 2023 $99.4 Million $717.7 Million $17.5 Million $600.7 Million
Q2 2023 $142.3 Million $713.6 Million $18.0 Million $607.1 Million
Q1 2023 $75.7 Million $722.2 Million $18.5 Million $627.6 Million
Q4 2022 $148.6 Million $754.8 Million $20.0 Million $656.1 Million
Q3 2022 $135.4 Million $782.0 Million $26.4 Million $685.4 Million

View All

ITCI Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 $489,000 -$53,000 $553.5 Million
Q1 2024 -$34.1 Million $0 -$7.9 Million
Q4 2023 -$2.1 Million -$1,000 $48.4 Million
Q3 2023 -$25.5 Million -$268,000 -$42.9 Million
Q2 2023 -$36.8 Million $0 $66.5 Million
Q1 2023 -$60.1 Million $0 -$72.9 Million
Q4 2022 -$39.2 Million $28,000 $13.3 Million
Q3 2022 -$231.8 Million -$806,000 $58.5 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions